LLY vs SEPN
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. SEPN: Septerna is a biotechnology company pioneering a new approach to unlock the therapeutic potential of G protein-coupled receptors (GPCRs) through oral small molecule drug discovery.
Side-by-side fundamentals
| Metric | LLY | SEPN | Edge |
|---|---|---|---|
| Price as of 2026-08-25 close | $1,233.66 | $41.30 | |
| Market cap as of 2026-08-26 | $1.16T | $1.9B | |
| P/E as of 2026-08-26 | 43.17 | n/a | |
| PEG as of 2026-08-26 | 1.48 | n/a | |
| Net margin as of 2026-08-26 | +33.5% | -49.9% | LLY higher |
| Gross margin as of 2026-08-26 | +83.4% | n/a | |
| Operating margin as of 2026-08-26 | +42.2% | -77.1% | LLY higher |
| ROE as of 2026-08-26 | +92.6% | -9.4% | LLY higher |
| ROA as of 2026-08-26 | +22.0% | -6.6% | LLY higher |
| Debt / equity as of 2026-08-26 | 1.62 | 0.00 | SEPN lower |
| Revenue growth (YoY) as of 2026-08-26 | +49.6% | +11790.1% | SEPN higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +1644.5% | SEPN higher |
| Dividend yield as of 2026-08-26 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-26 | 0.46 | 0.80 | |
| 1-year return as of 2026-08-25 close | +77.4% | +245.3% | SEPN higher |
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-25.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.